...
首页> 外文期刊>Drug development and industrial pharmacy >Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol Dispersing.
【24h】

Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol Dispersing.

机译:使用KinetiSol分散剂生产先进的固体分散体,以提高伊曲康唑的生物利用度。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVES: To investigate the ability of KinetiSol Dispersing to prepare amorphous solid dispersions of itraconazole using concentration-enhancing polymers. METHODS: Concentration-enhancing nature of several cellulosic polymers (HPMC, hypromellose acetate succinate) was studied using a modified in vitro dissolution test. Solid dispersions were prepared by KinetiSol Dispersing and characterized for solid-state properties using X-ray diffraction and differential scanning calorimetry. Potency and release characteristics were also assessed by high-performance liquid chromatography. Oral bioavailability of lead formulations was also assessed in animal models. RESULTS: Screening studies demonstrated superior concentration-enhancing performance from the hypromellose acetate succinate polymer class. Data showed that stabilization was related to molecular weight and the degree of hydrophobic substitution on the polymer such that HF > MF approximately LF, indicating that stabilization was achieved through a combination of steric hindrance and hydrophobic interaction, supplemented by the amphiphilic nature and ionization state of the polymer. Solid dispersions exhibited amorphous solid-state behavior and provided neutral media supersaturation using a surfactant-free pH change method. Rank-order behavior was such that LF > MF > HF. Addition of Carbopol 974P increased acidic media dissolution, while providing a lower magnitude of supersaturation in neutral media because of swelling of the high viscosity gel. In vivo results for both lead compositions displayed erratic absorption was attributed to the variability of gastrointestinal pH in the animals. CONCLUSIONS: These results showed that production of amorphous solid dispersions containing concentration-enhancing polymers through KinetiSol Dispersing can provide improved oral bioavailability; however, additional formulation techniques must be developed to minimize variability associated with natural variations in subject gastrointestinal physiology.
机译:目的:研究KinetiSol分散剂使用增强浓度的聚合物制备伊曲康唑无定形固体分散体的能力。方法:使用改良的体外溶出试验研究了几种纤维素聚合物(HPMC,醋酸羟丙甲纤维素琥珀酸酯)的浓度增强特性。固体分散体通过KinetiSol Dispersing制备,并使用X射线衍射和差示扫描量热法对固体性质进行了表征。效能和释放特性也通过高效液相色谱法评估。还在动物模型中评估了铅制剂的口服生物利用度。结果:筛选研究表明,醋酸羟丙甲纤维素琥珀酸酯聚合物具有更高的浓度增强性能。数据表明稳定化与分子量和聚合物上的疏水取代度有关,使得HF> MF约为LF,表明稳定化是通过空间位阻和疏水相互作用的组合实现的,并辅之以两亲性和电离态聚合物。固体分散体表现出无定形的固态行为,并使用无表面活性剂的pH改变方法提供中性介质过饱和。等级行为为:LF> MF> HF。由于高粘度凝胶的溶胀,添加Carbopol 974P可增加酸性介质的溶解度,同时在中性介质中提供较低的过饱和度。两种铅组合物的体内结果均显示出吸收不稳定,这归因于动物胃肠道pH的变化。结论:这些结果表明,通过KinetiSol Dispersing生产包含浓度提高的聚合物的无定形固体分散体可以改善口服生物利用度。然而,必须开发额外的制剂技术以使与受试者胃肠生理学的自然变化相关的可变性最小化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号